Available until 8/1/2024
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
story of the week
Subgroup Analyses of the Outcomes of Sacituzumab Govitecan Therapy for Metastatic TNBC
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ breast cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
NPJ Breast Cancer 2024 Apr 25;10(1)33, SA Hurvitz, A Bardia, K Punie, K Kalinsky, LA Carey, HS Rugo, V Diéras, S Phan, R Delaney, Y Zhu, SM TolaneyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
There is a critical need for improved therapy for patients with triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody–drug conjugate approved for the treatment of metastatic TNBC (IHC 0 or HER2-low). SG is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. Its approval for TNBC treatment was based on data from the phase III ASCENT trial, in which SG therapy resulted in statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with chemotherapy.
The subgroup analyses presented in the current study help to provide additional information regarding treatment efficacy in patients with a particularly high unmet need. Subgroup analyses help identify the different effects of treatments, ensuring that the benefits and risks of a drug are fully understood across a diverse population. Importantly, the current study was a post hoc analysis of efficacy and safety in patients by age, race, and the presence of brain metastases. The results confirmed the efficacy and safety of SG in these groups and further confirmed the activity of this highly active antibody–drug conjugate in patients with TNBC. By understanding how different subgroups respond to treatment, clinicians can make more informed treatment decisions for their patients.